A promising GBM oncotarget is a proteoglycan GPC-1, which is overexpressed in several cancers, including high- and low-grade gliomas and is associated with poor prognosis and resistance to therapy [36,37,38,39,40]. This evidence concerns the gene GPC1 and glioblastoma.